Gamida Cell (NASDAQ: GMDA) is one of 255 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Gamida Cell to similar businesses based on the strength of its dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and valuation.
Valuation & Earnings
This table compares Gamida Cell and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Gamida Cell||N/A||-$52.93 million||-1.09|
|Gamida Cell Competitors||$47.41 million||-$65.11 million||-21.82|
Gamida Cell’s peers have higher revenue, but lower earnings than Gamida Cell. Gamida Cell is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current ratings and recommmendations for Gamida Cell and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Gamida Cell Competitors||372||1484||3800||83||2.63|
Gamida Cell presently has a consensus target price of $19.40, indicating a potential upside of 68.70%. As a group, “Biotechnology” companies have a potential upside of 2.98%. Given Gamida Cell’s stronger consensus rating and higher probable upside, equities analysts plainly believe Gamida Cell is more favorable than its peers.
This table compares Gamida Cell and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Gamida Cell Competitors||-4,789.27%||-257.83%||-37.30%|
Insider and Institutional Ownership
1.7% of Gamida Cell shares are held by institutional investors. Comparatively, 51.7% of shares of all “Biotechnology” companies are held by institutional investors. 21.5% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Gamida Cell beats its peers on 8 of the 12 factors compared.
About Gamida Cell
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in a patients with high-risk blood cancers, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.